Pharmaceutical Technology® spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers.
The pharmaceutical industry has a significant impact on the environment that includes CO2 emissions, water consumption, use of plastics, and a variety of manufacturing practices (1). Therefore, sustainability and green manufacturing are becoming priorities for the pharmaceutical industry due to evolving and changing regulations to protect both the environment and patients.
Pharmaceutical Technology® spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers as they work with sponsors on the development and manufacture of drugs and biologics in a sustainable fashion that aligns with industry and regulatory requirements.
“Sponsors are increasingly requiring sustainable or green manufacturing practices when negotiating for partnerships with Neuland,” says Davuluri. “I think this trend is also kind of aligned with the broader industry shift towards sustainability … we are seeing that a lot of these companies are having their own approach on or their own frameworks in what they would like to measure their partners with. This is not just about Europe versus US, but also within a particular geography, every company has a different approach. Earlier, we used to see only big pharma or large generic companies having particular requirements. But now we're even seeing a lot of small to mid-sized biotechs talking to us and measuring us on our sustainability related practices as well.”
Click the video above to watch the interview.
1. Di Russo, M.; Zjalic, D.; Lombardi, G.S.; Perilli, A.; Congedo, G.; Daugbjerg, S.; Cadeddu, C. Impact of the 50 Biggest Pharma Companies: A Review of Environmental Report Aspiring to NetZero. European Journal of Public Health2023, 33, Issue Supplement_2 https://doi.org/10.1093/eurpub/ckad160.1182
Saharsh Davuluri is Vice-Chairman and Managing Director, Neuland Laboratories. Saharsh is an electrical engineering graduate and obtained his master’s in management information systems from Weatherhead School of Management, Cleveland, Ohio, USA. He also secured Master of Business Administration from University of North Carolina, USA. He has worked in the past with Sify Limited in various roles in the Sales organization. He joined Neuland in 2007, with responsibility for initiating the Custom Manufacturing Solutions (CMS) business. He is currently responsible for all marketing, information technology (IT), and business development activities along with oversight of R&D.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.